Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Outcomes of Patients With HER2-positive (HER2+) Metastatic Breast Cancer (mBC) After Treatment With Trastuzumab Deruxtecan (T-DXd) in the United States

NCT06833268 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06833268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06833268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Outcomes of Patients With HER2-positive (HER2+) Metastatic Breast Cancer (mBC) After Treatment With Trastuzumab Deruxtecan (T-DXd) in the United States
Lead sponsor
Daiichi Sankyo
Phase
Observational
Overall status
Completed
Start date
January 20, 2025
Completion date
June 16, 2025
Enrollment
228 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer